Kevin O'Boyle
About Kevin O’Boyle
Kevin O’Boyle was appointed to Outset Medical’s Board of Directors effective May 14, 2025, as an independent director and Chair of the Audit Committee; the Board also determined he qualifies as an “audit committee financial expert.” He holds a B.S. in Accounting from Rochester Institute of Technology and brings over two decades of healthcare leadership experience, including CFO roles and multiple public-company directorships . His initial board term is Class I through the 2027 annual meeting or until a successor is elected .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| NuVasive, Inc. | Chief Financial Officer | Jan 2003–Dec 2009 | Scaled medtech finance function; capital equipment/recurring revenue familiarity |
| Advanced Biohealing Inc. | SVP & Chief Financial Officer | Dec 2010–Jul 2011 (company acquired) | Transaction execution and integration readiness |
| ChromaVision Medical Systems, Inc. | Leadership roles | ~6 years (dates not specified) | Early-career operating leadership in medtech |
External Roles
| Organization | Role | Tenure/Status | Notes |
|---|---|---|---|
| Nevro Corp. | Director | Mar 2019–Apr 2025 | Company acquired by Globus Medical in Apr 2025 |
| GenMark Diagnostics, Inc. | Chairman | Until May 2021 | Acquired by Roche in May 2021 |
| Sientra, Inc. | Director | May 2014–Jun 2023 | Medical aesthetics; prior career ties via Eko/SeaSpine ecosystem not implicated here |
| Wright Medical Group N.V. | Director | Nov 2015–Nov 2020 | Acquired by Stryker |
| Zeltiq Aesthetics, Inc. | Director | Jul 2011–Apr 2017 | Acquired by Allergan |
| Durata Therapeutics, Inc. | Director | May 2012–Nov 2014 | Acquired by Actavis |
| Carlsmed (private) | Director | Current | Personalized spine surgery solutions |
Board Governance
- Committee assignments: Audit Committee Chair, effective May 14, 2025; Audit membership was reconstituted to transition chair from Patrick Hackett to O’Boyle and remove Andrea Saia; Compensation Chair moved to D. Keith Grossman and Saia joined Compensation .
- Independence: Board determined O’Boyle is independent under SEC and Nasdaq rules; also designated an audit committee financial expert .
- Board/committee activity level: The Board met 15 times in 2024; Audit Committee met 10 times; Compensation met 7 times; Nominating & Corporate Governance met 5 times. All incumbent directors met at least the 75% attendance threshold in 2024 (O’Boyle joined in 2025) .
- Stock ownership guidelines: Covered directors must hold stock equal to 3x the annual Board cash retainer within five years of Feb 2, 2023 or their designation date; unvested time-based RSUs count; compliance measured annually; anti-hedging and anti-pledging policies prohibit short sales and pledging/margin accounts .
Fixed Compensation
| Component | Policy Terms | Amount |
|---|---|---|
| Board member annual cash retainer | Paid quarterly in arrears; prorated for partial months | $45,000 |
| Lead Independent Director additional retainer | Additional to Board retainer | $45,000 |
| Audit Committee Chair | Annual chair fee | $20,000 |
| Audit Committee member | Annual member fee | $10,000 |
| Compensation Committee Chair | Annual chair fee | $20,000 |
| Compensation Committee member | Annual member fee | $10,000 |
| Nominating & Corporate Governance Chair | Annual chair fee | $10,000 |
| Nominating & Corporate Governance member | Annual member fee | $5,000 |
Notes:
- O’Boyle will be compensated consistent with the non-employee director policy described in the April 11, 2025 proxy .
- Director equity grants subject to equity plan share availability; grants may be suspended if shares are insufficient and made later when shares become available (Board modifications in Mar 2025) .
Performance Compensation
| Equity Type | Grant Context | Vesting/Terms | Value Policy |
|---|---|---|---|
| Initial RSUs (time-based) | Granted upon board appointment | Vests quarterly over 3 years, subject to continuous service | $280,000 grant-date value (policy updated Feb 2025) |
| Annual RSUs (time-based) | Granted for continuing service after annual meeting | Vests at earlier of 1-year anniversary or next annual meeting, subject to service | $160,000 grant-date value; 2024 share cap of 1,666 shares was removed in 2025 |
| Change-in-control treatment | For all director equity | Full vesting of outstanding director equity upon change in control if in continuous service until closing | Policy applies to non-employee directors |
Directors do not receive performance-conditioned equity (e.g., PSUs); their compensation is predominantly time-based RSUs aligned to continued service and shareholder value creation .
Other Directorships & Interlocks
| Company | Sector | Overlap/Interlock Considerations |
|---|---|---|
| Nevro, Wright Medical, Zeltiq, Sientra, GenMark, Durata | Medtech/biopharma | Historical directorships; several ended due to acquisitions; no OM-related related-party transactions disclosed for O’Boyle |
| Carlsmed (private) | Medtech | Private company; no related-party transactions disclosed |
Expertise & Qualifications
- Audit chair experience and designation as “audit committee financial expert,” reinforcing oversight of financial reporting, controls, and external audit .
- Deep finance and transaction execution background from CFO roles at NuVasive and Advanced Biohealing, plus broad medtech board experience across capital equipment and recurring revenue models relevant to Outset .
- Formal accounting training (B.S. in Accounting, RIT) underpinning audit leadership credentials .
Equity Ownership
| Item | Detail | Source |
|---|---|---|
| Stock Ownership Guidelines | Directors must hold 3x annual Board cash retainer within 5 years; unvested time-based RSUs count | |
| Anti-hedging/anti-pledging | Prohibits short sales, options, margin accounts, and pledging | |
| Form 3 (Initial beneficial ownership) | Filed May 14, 2025, reporting status as Director | |
| Form 4 (RSU grant) | RSUs granted on May 14, 2025; subsequent filing on June 4, 2025 |
Governance Assessment
- Strengthened audit oversight: Transitioning Audit Committee chair to an experienced CFO and designated “financial expert” should enhance financial reporting rigor, auditor oversight, and risk management, including cybersecurity and related-person transaction approval processes handled by the Audit Committee .
- Independence and conflicts: The Board affirmed independence; no transactions requiring Item 404(a) disclosure; O’Boyle will sign the standard indemnification agreement—overall low conflict risk and aligned governance posture .
- Compensation alignment: Director pay structure is market-benchmarked (Pearl Meyer) and primarily equity-based RSUs with change-in-control acceleration; stock ownership guidelines and anti-hedging/pledging policies bolster alignment with shareholders .
RED FLAGS
- None disclosed: No related-party transactions; independence confirmed; anti-pledging policy in place; attendance will be observable in future proxies (joined post-2024) .